Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.
about
How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancerMeta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapyWater exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy.Magnetic resonance imaging shrinkage patterns following neoadjuvant chemotherapy for breast carcinomas with an emphasis on the radiopathological correlationsMRI in breast cancer therapy monitoringFrequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient.Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging.Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.Correlation between Blood Flow Signal of Color Flow Imaging and Nottingham Prognostic Index in Patients with Breast Carcinoma.Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-AnalysisEarly prediction of response to neoadjuvant chemotherapy for locally advanced breast cancer using MRIBevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.Changes of T2 Relaxation Time From Neoadjuvant Chemotherapy in Breast Cancer Lesions.Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology.Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
P2860
Q26798419-660BA1FB-9AE1-49E4-8982-DADC042D9B57Q27024544-F0B9DB99-5654-4E7D-87ED-7B08FE03D196Q30651989-D476D892-3A68-436F-9C6E-4A979FE11561Q33933029-B7553BE7-3CD9-42AE-A929-A7235A958BAFQ33938324-708C45DB-8E78-4D31-9C93-DB234D7A286AQ34074868-5F38D49A-81BE-4A75-89F4-6D9FA14A467AQ34940150-B3B4D350-51A3-4EBA-831C-A30080132FBFQ35560975-6611E8EE-4F3A-4A74-8BE6-C02612A4C672Q35928203-2AA6D26E-742D-4DF9-AB66-30A6D047B941Q36036146-AB557492-1FD4-4B45-A03A-84E869CF13A7Q36118278-AA13EB8A-F0C7-45CE-8AFF-FA100E9250A3Q36797054-874C8828-4C32-4498-AB18-CA4F569F904EQ37180350-40083896-8B13-422C-B257-C48200DB5662Q37410448-E10CA7D9-86AC-44BC-8E8A-72E537FEA623Q37734922-40BD51CB-A3B9-4865-A323-E10B59E8457EQ44491240-9868C551-AE79-40B8-A135-DC2804E0CDB9Q53080309-B542B1DC-05EF-4BEC-A62D-7DAD4275977CQ54446011-B811C146-D440-4B6B-AF5B-87C9232F861D
P2860
Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Residual breast cancer diagnos ...... with and without bevacizumab.
@en
Residual breast cancer diagnos ...... with and without bevacizumab.
@nl
type
label
Residual breast cancer diagnos ...... with and without bevacizumab.
@en
Residual breast cancer diagnos ...... with and without bevacizumab.
@nl
prefLabel
Residual breast cancer diagnos ...... with and without bevacizumab.
@en
Residual breast cancer diagnos ...... with and without bevacizumab.
@nl
P2093
P2860
P1476
Residual breast cancer diagnos ...... with and without bevacizumab.
@en
P2093
Jeon-Hor Chen
Min-Ying Su
Orhan Nalcioglu
Philip M Carpenter
Rita S Mehta
Shadfar Bahri
Soon-Young Kwon
P2860
P2888
P304
P356
10.1245/S10434-009-0441-5
P577
2009-03-31T00:00:00Z
P5875
P6179
1036272912